Navigation Links
Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians' Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia

Future Therapies Modeled After Johnson & Johnson/Basilea's or Forest/Novexel's Drug Could Be Used As First-Line Therapies, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that activity against drug-resistant pathogens is one of the leading drug attributes influencing surveyed physicians' antibiotic selection for the treatment of inpatient community-acquired pneumonia. Due to the difficulty of obtaining adequate samples for microbiological testing, physicians rely on empiric therapies that can cover key pathogens, particularly resistant and susceptible strains of Streptococcus pneumoniae. In fact, one of the key trends surveyed physicians foresee in the next five years is to prescribe an empiric therapy that covers methicillin-resistant Staphylococcus aureus (MRSA) for inpatients with community-acquired pneumonia.

The new report entitled Hospital Anti-Infectives Insight Series: Community-Acquired Pneumonia also finds that future therapies modeled after Johnson & Johnson/Basilea's ceftobiprole or Forest/Novexel's ceftaroline could be used as empiric first-line therapies for very severe cases of community-acquired pneumonia requiring admission to the ICU or mechanical ventilation.

"Ceftobiprole and ceftaroline couple broad-spectrum cephalosporin activity with targeted activity against MRSA, offering physicians enhanced pathogen coverage for empiric treatment of community-acquired pneumonia in the hospital setting," stated Lisa Arias, analyst at Decision Resources. "We anticipate that future therapies modeled after these agents will gain substantial usage in the market for the treatment of inpatient community-acquired pneumonia and potentially displace usage of older, generically available cephalosporins, due to their anti-MRSA activity."

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                 Elizabeth Marshall
    Decision Resources              Decision Resources, Inc.
    781-296-2691                    781-296-2563

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Physical activity guidelines are too confusing, say researchers
2. CRH experiences significant increase in business activity
3. Flu Activity Increases in the U.S.
4. Durability of dental fillings improves if the enzyme activity of teeth is inhibited
5. Regular physical activity linked to better quality of life in early-stage lung cancer survivors
6. Huron Capital Continues Acquisition Activity
7. Altered brain activity in schizophrenia may cause exaggerated focus on self
8. School-based physical activity: Has benefits even if it doesnt help lose weight
9. Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity
10. Reduced breast cancer risk: Physical activity after menopause pays off
11. Physical activity, mood and serious mental illness
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa ... and Sepsis conditions present in similar ways and require time-critical intervention to avoid large ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, ... choose to buy during the Black Friday and Cyber Monday massage chair sales ... search the Internet high and low to find the best massage chair deals, they ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology: